Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition

• Autores: Anne Y. Liu
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 34, Nº. 2, 2020 (Ejemplar dedicado a: Infections Related to Biologics), págs. 211-234
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Targeting interleukins that drive innate inflammation has expanded treatments of autoinflammatory and autoimmune disorders. Interleukin (IL)-1 inhibition has proven useful for monogenic autoinflammatory syndromes, and IL-6 inhibition for autoimmune arthritides. Biological therapies impeding these pathways impair detection and containment of pathogens, particularly invasive bacteria, reflecting the importance of IL-1 and IL-6 in communicating danger throughout the immune system. Biologics targeting T helper type 2 inflammation are used to treat specific allergic, atopic, and eosinophilic diseases. They may impair protections against local herpesvirus reactivations while augmenting antiviral responses to respiratory viruses. Their risks with helminth exposures have yet to be defined.